Results 111 to 120 of about 299,998 (141)

[Alcohol liver disease: immunoregulatory mechanisms and precision therapeutic targets]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Shen HY, Wei LM, Zuo L, Wang H.
europepmc   +1 more source

[A case of acetaminophen-induced cholestatic liver injury accompanying severe hypercholesterolemia in children]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Chen L, Gao XY, Liu XY, Shao YL.
europepmc   +1 more source

[The Influence of Hepatitis B Virus on Sex Hormone Levels and Quality of Life in Female Hepatitis B Patients With Different Alanine Aminotransferase States]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban
Gao P, Zhou W, Li J, Yao L.
europepmc   +1 more source

[Analysis of the efficacy and survival outcomes of plasma exchange combined with dual plasma molecular adsorption system therapy in liver failure]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Ding JJ, Bao L, Cao WJ, Ning L, Xiao H, Li WY, He HL.   +6 more
europepmc   +1 more source

[Analysis of epidemiological characteristics and spatial clustering of hepatitis C virus in China from 2018 to 2022]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Fan SF, Zhang JH, Duan ZH, Dai Z, He QY.
europepmc   +1 more source

[Construction of a predictive model for recompensation in patients with decompensated viral hepatitis-induced cirrhosis]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Xu DQ, Mu H, Sa CF, Zhang YY, Mou CY, Liu L.   +5 more
europepmc   +1 more source

[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B.
europepmc   +1 more source

[A statistical survey of infectious disease awareness among university freshmen in Hunan Province: Knowledge gaps regarding HPV infection and their moderating factors]. [PDF]

Zhong Nan Da Xue Xue Bao Yi Xue Ban
Liu L, Yuan X.
europepmc   +1 more source

[Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Wang XY, Sun HM, Gao YH.
europepmc   +1 more source